{"aliases":[{"type":"CodeName","name":"AG-120"},{"type":"Synonym","name":"IDH1 inhibitor AG-120"},{"type":"USBrandName","name":"Tibsovo"},{"type":"CASRegistryName","name":"1448347-49-6"}],"definition":{"html":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","text":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib","text":"Ivosidenib"},"nciConceptId":"C114383","nciConceptName":"Ivosidenib","termId":758551,"name":"ivosidenib","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ivosidenib"}